Of note, alectinib was found to have a better outcome than crizotinib (pCR: 37.5% vs. 15.4%) in a retrospective study of patients with stage III ALK-positive NSCLC who had received surgery after induction therapy of alectinib (n = 16) or crizotinib (n = 13) [62]. The gene discussed is ALK; the disease is non-small cell lung carcinoma.